Bookmark and Share

Minesh P Mehta
View Curriculum Vitae 

Minesh P Mehta M.B.Ch.B., F.A.S.T.R.O.

Academic Title: Professor
Primary Appointment: Radiation Oncology
Administrative Title: Medical Director, Maryland Proton Treatment Center (Mptc)
mmehta@umm.edu
Location: UMMC GGJ-82
Cell: 608 695 6714

Personal History:

Minesh Mehta, M.B.Ch.B., received his medical degree from the University of Zambia in 1981 and after completing an initial internship, he proceeded to complete residency training in Radiation Oncology at the University of Wisconsin in 1988, following which he was appointed to the faculty of the University of Wisconsin's School of Medicine in the Department of Human Oncology. In 1997, he was appointed as the Chairman of the Department of Human Oncology, which he led for the subsequent 10 years.

During this time period, he rose to the rank of Professor with Tenure, and raised the Department to national recognition through an intensive phase of growth in research funding, publications output, technology development, faculty hires and growth, programmatic development, and patient services expansion at a statewide level, creating a broad cancer services network. He was instrumental in multiple refunding cycles of the Imaging and Radiation Sciences Program of the University of Wisconsin Cancer Center, PI of several grants, including a Program Project PO1 grant, and several others. He has successfully lead the RTOG Brain Tumor Program for over 15 years, with continuous grant refunding. From 2010-12, Dr. Mehta was Professor of Radiation Oncology at Northwestern University where he was also co-leader of the Lurie Cancer Center's Solid Tumor Investigational Program.

Dr. Mehta's clinical activities have revolved around thoracic and central nervous system tumors where he has gained international recognition and acclaim, based on his clinical and academic productivity, which includes several hundred manuscripts, abstracts, book chapters, and speaker invitations. He has developed robust clinical research programs with an eye toward generating level 1, practice-changing evidence. His research has also include several innovations in areas including radiosensitizers, radioprotectors, radiation oncology technology, specifically intensity modulated, image-guided radiation therapy, etc.

Dr. Mehta has had several leadership responsibilities, including Departmental Chairmanship, residency program directorship, medical school course directorship, leadership in several national organizations such as ASCO, ASTRO, SNO, ABS, ISRS, FDA, etc. He has also been very active in medical student, graduate student, and resident education.

Research Interests:

Radiation Oncology, Radiosensitizers, Radiosurgery, Proton Therapy, IMRT, IGRT, CNS Tumors, Thoracic Oncology, Combined Modality Therapy, Clinical Trials

Clinical Speciality:

Radiation Oncology


Grants & Contracts:

2009-2014 RTOG CA 21661-36-41: RTOG: PI: Curran W, Brain Tumor Committee Chair: Mehta M, ~$60,000,000, 5% effort and salary.


Publications:

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin NL, Mehta M: Summary Report on The Graded Prognostic Assessment (GPA): An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival, Guide Treatment and Stratify Clinical Trials for Patients with Brain Metastases, J Clin Oncol, 30:419-425, 2012.

Preusser M, Capper D, Ilhan A, Berghoff A, Birner P, Bartsch R, Marosi C, Zielinski C, Winkler F, Mehta M, Wick W, von Deimling A: Pathobiology and Emerging Targeted Therapies in Brain Metastases, Acta NeuroPathologica, 123: 205-222, 2012.

Tsao MA, Khuntia D, Mehta MP: Brain Metastases: Whatâ?Ts New With an Old Problem? Curr Opin Support Palliat Care, 6:85-90, 2012.

Caine C, Mehta MP, Laack NN, Gondi V: Cognitive Function Testing in Adult Brain Tumor Trials: Lessons from a Comprehensive Review. Expert Rev AntiCa Ther, 12:655-667, 2012.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda M, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan C, Heguy A, Liau L, Lieberman F, Yung WKA, Gilbert M, Reardon D, Drppatz J, Wen P, Lamborn K, Chang S, Prados M, Fine H, Horvath S, Wu N, Lassman A, DeAngelis L, Yong W, Kuhn J, Mischel P, Mehta M, Cloughesy T, Mellinghoff I: Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors, Ca Disc 2:458-471, 2012.

Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH: A Randomized Phase III Study Of Thoracic Radiation In Combination With Paclitaxel And Carboplatin With Or Without Thalidomine In Patients With Stage III Non-Small Cell Lung Cancer: An Eastern Cooperative Oncology Group Sudy (ECOG 3598), J Clin Oncol, 30:616-622, 2012.

Nieder C, Grosu AL, Mehta MP: Brain Metastases Research 1990-2010: Pattern of Citation and Systematic Review of Highly Cited Articles, Sc World J (online J), Article ID 721598, 2012.

Sperduto P, Kased NW, Roberge D, Xu Z, Shanley R, Luo X, Sneed P, Chao S, Weil R, Suh J, Bhatt A, Jensen A, Brown P, Shih H, Kirkpatrick J, Gaspar L, Fiveash J, Chiang V, Knisely J, Sperduto C, Lin N, Mehta M: Reply to Chamberlain et al, J Clin Oncol, 30:3316-17, 2012.

Gondi V, Herman B, Mehta MP, Tome WA: Hippocampal Dosimetry Predicts Neurocognitive Function Impairment Following Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors, Int J Radiat Oncol Biol Phys, 83:487-93, 2012.

Barnholtz-Sloan JS, Yu C, Sloan AE, Wang M, Dignam J, Vogelbaum MA, Mehta M, Machtay M, Kattan MW: A nomogram for individualized prediction of survival for brain metastasis patients, NeuroOncol, 14:910-18, 2012.

Gondi V, Tome W, Mehta MP: In response to Kirby et al, Physics Strategies for Sparing Neural Stem Cells During Whole-Brain Radiation Treatments, Med Phys 39:1677-78, 2012.

Ogiwara H, Kalakota K, Rakhra SS, Helenowski IB, Marymont MH, Kalapurakal JA, Mehta MP, Levy RB, Chandler JP: Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases, J Neuro Oncol, 108:141-146, 2012.

Gilbert MR, Kuhn J, Lamborn K, Lieberman F, Wen P, Mehta M, Cloughsey T, Lassman AB, DeAngelis L, Chang S, Prados M: Cilengitide in Patients with Recurrent Glioblastoma: The Results of NABTC 03-02, a Phase II Trial with Measures of Treatment Delivery. J NeuroOncol, 106:147-153, 2012.

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Xianghua Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Lin N, Mehta M: Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients with Breast Cancer and Brain Metastases, Int J Radiat Oncol Biol Phys, 82:2111-17, 2012.

Shaw EG, Wang M, Coons SW, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert M, Mehta M: Randomized Trial Of Radiation Therapy Plus Procarbazine, Lomustine And Vincristine Chemotherapy For Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802, J Clin Oncol, 30:3065-70, 2012.